Serina Therapeutics shares surge 30.15% intraday after FDA clears IND application for SER-252.

Serina Therapeutics surged 30.15% intraday after the FDA cleared its Investigational New Drug (IND) application for SER-252, an apomorphine-based therapy for advanced Parkinson’s disease. The clearance, announced in a detailed press release, allows the company to advance Phase 1b clinical trials under a 505(b)(2) NDA pathway, positioning SER-252 for potential regulatory efficiency. CEO Steve Ledger emphasized the milestone as a validation of the drug’s development strategy and its potential to address unmet medical needs. The news overshadowed a separate insider sale by the CSO and aligns with broader investor optimism around the company’s POZ Platform-enabled pipeline. The FDA clearance directly fueled the sharp intraday rally, reflecting confidence in the therapeutic’s clinical and commercial prospects.